Mixed phenotype acute leukemia

Researchers are testing whether adding abatacept to standard immune-suppressing drugs can prevent severe graft-versus-host disease after a double umbilical cord blood transplant. The trial enrolls people with blood cancers such as leukemia, lymphoma, and myelodysplastic syndromes…

This phase 2 trial tests whether combining venetoclax and azacitidine after a stem cell transplant can prevent leukemia from returning in high-risk patients. About 100 adults aged 18-75 with certain types of acute leukemia who are in remission after transplant will receive the dr…

This study tests whether removing a specific type of immune cell (naive T cells) from donor stem cells can prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers. GVHD occurs when donor cells attack the patient's body after a stem cell tr…

This study tests a new oral drug (revumenib) combined with standard chemotherapy for infants and young children with a specific type of leukemia (KMT2A-rearranged) that has returned or not responded to treatment. The goal is to see if the combination is safe and works better than…

This early-stage study tested a combination of three immunotherapy drugs (blinatumomab, nivolumab, and ipilimumab) in 28 adults with a severe form of B-cell leukemia that had returned or not responded to prior treatments. The main goal was to find safe doses and identify side eff…

This study aimed to find a safe dose of revumenib when given with standard chemotherapy drugs for children and young adults with acute leukemia. It was designed for patients with certain genetic markers. However, the trial was withdrawn before any participants were enrolled, so n…

This phase 3 trial tests imatinib, a targeted cancer drug, with two different chemotherapy backbones in children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if a less intense chemo regimen works as well as the s…

This study tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. It uses a special mix of stem cells and immune cells from a donor to help the body accept the transplant while reducing serious side effects like graft-versus-host disease. The go…

This phase 3 trial compares two types of stem cell transplants for children, adolescents, and young adults with acute leukemia or myelodysplastic syndrome (MDS). One uses a half-matched family donor (haploidentical), the other a fully matched unrelated donor. The goal is to see w…

This early-phase trial tests a new targeted drug called pivekimab sunirine (PVEK) alongside a standard chemotherapy regimen (FLAG-Ida) in 30 adults with newly diagnosed, high-risk acute myeloid leukemia or related blood cancers. PVEK works like a smart bomb, attaching to a protei…

This trial tests whether adding two drugs—vorinostat and low-dose azacitidine—after a stem cell transplant can help prevent relapse in children with certain myeloid cancers. The study includes children aged 1 to 21 with acute myeloid leukemia or related conditions. Researchers ar…

This study tests whether using each child's unique genetic information to guide treatment can improve outcomes for acute lymphoblastic leukemia and lymphoma. About 790 children aged 1-18 will receive a combination of chemotherapy and newer targeted therapies, such as CAR T cells …

This early-phase study tests a new drug called uproleselan combined with two standard chemotherapy drugs for children and teens with acute myeloid leukemia or related blood cancers that have returned or not responded to treatment. The drug works by blocking a protein that helps c…

This early-phase trial is testing the drug selinexor (KPT-330) in 16 children and young adults with leukemia that has come back or not responded to standard treatments. The main goal is to find the safest dose and understand side effects. The drug works by blocking a protein that…

This study tests a new drug called ziftomenib (KO-539) in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug targets a specific genetic change (MLL rearrangement or NPM1 mutation) found in some patients. The goal is to find the saf…

This was a very early (Phase 1) study to test the safety of a new drug called MT-0169 in people with certain types of acute leukemia (AML or T-ALL) that had come back or not responded to treatment. The drug was given through a vein. However, the study was withdrawn before any pat…

This early-phase study tests a stem cell transplant method for people with advanced blood cancers like leukemia. Instead of using strong drugs to prevent complications, doctors give specially selected immune cells (regulatory T-cells) along with regular T-cells to help the body a…

This study was designed to test the safety and best dose of the drug revumenib in children and young adults with certain types of leukemia (ALL, AML, or mixed phenotype) after they have received a stem cell transplant. The goal was to see if revumenib could help prevent the cance…

This early-phase trial is testing whether adding the drug venetoclax to a standard treatment regimen can help adults with a specific type of leukemia (Philadelphia chromosome-positive ALL). The study involves 20 participants and aims to find the safest dose of venetoclax when com…

This study tests a combination of three drugs (homoharringtonine, venetoclax, and azacitidine) in 40 adults newly diagnosed with a rare and aggressive leukemia called mixed-phenotype acute leukemia (MPAL). The goal is to see if this drug combo can safely help more patients achiev…

This study compares stem cell transplants from two types of donors for people with leukemia or myelodysplastic syndromes (MDS): younger non-family members (age 40 or under) and older first-degree relatives (over 50). The goal is to see which donor leads to better overall survival…

This study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to help prevent the donor cells from attacking the patient's body. The goal is to see if th…

This phase 3 trial tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. Orca-T is a special mix of stem cells and immune cells from a matched donor, designed to reduce a serious side effect called graft-versus-host disease. The study compares …

This study tests an oral drug called BN104 in adults and adolescents with acute leukemia that has come back or not responded to treatment. The drug targets specific genetic changes (KMT2A rearrangement or NPM1 mutation) that drive the cancer. The trial aims to check safety, how t…

This trial is testing whether adding two targeted drugs, venetoclax and navitoclax, to standard chemotherapy can help children and young adults with acute lymphoblastic leukemia (ALL) that has come back or not responded to treatment. The study has two phases: first, finding the b…

This study tests whether adding levocarnitine, a natural nutrient, to standard chemotherapy can prevent severe liver damage in teens and young adults (ages 15-39) with leukemia or lymphoma. About 440 participants will receive either chemotherapy alone or chemotherapy plus levocar…